Boldenone
Also known as: Equipoise, EQ, Boldenone Undecylenate, Bold
Anabolic-Androgenic Steroid | Lean Mass & Vascularity
Overview
Boldenone is a synthetic anabolic-androgenic steroid derived from testosterone by the introduction of a 1,2-double bond (dehydrogenation at the C1-C2 position). It was originally developed in the 1960s as a long-acting injectable veterinary steroid under the trade name Equipoise for use in horses. Boldenone has never been approved by the FDA for human medical use, and no pharmaceutical-grade human formulation has been marketed. Despite its veterinary origins, boldenone has become one of the more widely used anabolic steroids in bodybuilding and strength sports, valued for producing lean, quality muscle gains with less water retention than testosterone, enhanced vascularity, increased appetite, and a notable boost in red blood cell production and endurance capacity. Its anabolic rating is approximately 100 (equal to testosterone), while its androgenic rating is roughly 50 (half that of testosterone), giving it a favorable anabolic-to-androgenic ratio. Boldenone aromatizes to estradiol at approximately 50% the rate of testosterone, and the compound itself has been reported to possess mild aromatase inhibitor-like properties through its metabolite 1,4-dienedione. The undecylenate ester produces a very long-acting compound with a half-life of approximately 14 days, meaning effects build slowly and the compound has a prolonged detection window of roughly 5 months in anti-doping tests.
Key benefits
- Lean, quality muscle gains with minimal water retention compared to testosterone
- Enhanced vascularity through increased red blood cell production and reduced subcutaneous water
- Significant increase in appetite, supporting caloric surplus during mass-gaining phases
- Potent stimulation of erythropoiesis, increasing oxygen-carrying capacity and endurance
- Lower estrogenic activity than testosterone, reducing the need for aromatase inhibitors
- Lower androgenic side effects (hair loss, acne, prostate stimulation) than testosterone
- Favorable anabolic-to-androgenic ratio (100:50 compared to testosterone at 100:100)
- Improved collagen synthesis reported anecdotally, supporting joint and connective tissue health
Mechanism of action
Boldenone exerts its anabolic effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and increased IGF-1 output in muscle tissue. The 1,2-double bond modification reduces the compound's affinity for 5-alpha reductase, meaning boldenone is not efficiently converted to a more potent dihydro-metabolite in the way testosterone is converted to DHT. Instead, boldenone is reduced by 5-alpha reductase to dihydroboldenone (1-testosterone), a distinct metabolite with its own androgenic profile. This structural difference contributes to boldenone's lower androgenic activity in skin, prostate, and hair follicle tissues compared to testosterone. Boldenone is a potent stimulator of erythropoietin (EPO) production in the kidneys, increasing red blood cell mass and oxygen-carrying capacity to a degree that exceeds most other anabolic steroids at comparable doses. This erythropoietic effect is the primary mechanism behind the increased vascularity and endurance commonly reported by users, but it also represents the compound's most significant health risk, as unchecked hematocrit elevation can increase blood viscosity and cardiovascular event risk. Boldenone aromatizes to estradiol at roughly half the rate of testosterone, and its metabolite 1,4-dienedione acts as a mild aromatase inhibitor, which collectively result in lower estrogenic activity than equidose testosterone. This reduced aromatization contributes to the drier, leaner aesthetic associated with boldenone use. An important practical consideration: approximately 50% of users experience noticeable downward estrogen pressure from boldenone, requiring either reduced AI dosing or an increased testosterone-to-boldenone ratio to avoid low-estrogen symptoms (joint pain, flat mood, low libido). The other 50% do not experience this effect to a significant degree. Because of this individual variability, it is recommended to start with a 2:1 testosterone-to-EQ ratio and adjust based on bloodwork and symptom assessment rather than assuming a fixed AI or testosterone dose will be appropriate.
Molecular data
- Type
- 1-dehydrotestosterone steroid (C19H26O2)
- Half-life
- ~14 days (undecylenate)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Body Composition
Performance / Endurance
Veterinary (Original Indication)
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200-400 mg/week | 1-2x per week (undecylenate) | — |
| — | 400-600 mg/week | 2x per week (undecylenate) | — |
| — | 600-700 mg/week | 2x per week (undecylenate) | — |
| — | 200-400 mg/week | Every 3-4 days | — |
Protocol variations
Alternative cycling patterns reported in the literature and community.
Boldenone Undecylenate (Equipoise)
Boldenone undecylenate is the original and overwhelmingly dominant ester form, sold under the veterinary trade name Equipoise. Its 14-day half-life makes it one of the longest-acting injectable steroids available. Blood levels build gradually over the first 4-6 weeks and remain elevated for weeks after the final injection. This pharmacokinetic profile means cycles should be planned for 16-20 weeks minimum and post-cycle therapy timing must account for the prolonged clearance period. The undecylenate ester is notable for being liquid at room temperature, which contributes to boldenone's reputation for painless injections and easy handling.
Boldenone Cypionate
Boldenone cypionate is a shorter-acting ester formulation with a half-life of approximately 7-8 days, comparable to testosterone cypionate. It reaches stable blood levels faster than the undecylenate ester (within 2-3 weeks) and clears the system more quickly after discontinuation, allowing for shorter cycle lengths of 10-14 weeks and earlier initiation of post-cycle therapy. Boldenone cypionate is significantly less common than undecylenate and is produced by fewer underground labs, making availability and quality verification more challenging. Some users report that the shorter ester allows them to experience boldenone's effects sooner and manage side effects (particularly hematocrit elevation) more responsively.
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Increased hematocrit and red blood cell count (the primary and most clinically significant side effect, more pronounced than with most other AAS)
- Increased appetite (significant and dose-dependent, can be a benefit or hindrance depending on goals)
- Anxiety and restlessness ('EQ anxiety' is widely reported anecdotally, particularly at higher doses or in anxiety-prone individuals)
- Mild acne and oily skin (less than testosterone due to lower androgenic activity)
- Suppression of endogenous testosterone production (profoundly suppressive, as with all AAS)
- Mild hair thinning in genetically predisposed individuals (less than testosterone but not absent)
- Elevated blood pressure secondary to increased blood volume from erythrocytosis
- Increased vascularity (cosmetic effect, but indicative of elevated RBC)
Rare side effects
- Polycythemia requiring therapeutic phlebotomy (hematocrit exceeding 54%)
- Significant cardiovascular strain including left ventricular hypertrophy with prolonged use
- Adverse lipid profile changes (HDL suppression, LDL elevation)
- Gynecomastia (uncommon due to lower aromatization rate, but possible)
- Low estrogen symptoms when boldenone dose exceeds testosterone dose (due to AI metabolite effect)
- Insomnia and night sweats at higher doses
- Kidney stress (boldenone metabolites are renally cleared and some users report dark urine at high doses)
- Injection site reactions (rare with undecylenate ester due to its liquid nature)
Contraindications
- Polycythemia or elevated hematocrit (above 50% at baseline)
- Cardiovascular disease, coronary artery disease, or history of thromboembolic events
- Hepatic impairment or liver disease
- Prostate cancer (active or history of hormone-sensitive prostate cancer)
- Pre-existing anxiety disorders (boldenone may significantly exacerbate anxiety symptoms)
- Pregnancy or potential for pregnancy (Category X)
- Known hypersensitivity to boldenone or any formulation components
- Renal impairment (boldenone metabolites are renally cleared)
Monitoring
- Complete blood count with hematocrit: baseline, 6-8 weeks, then every 6-8 weeks throughout cycle (MOST CRITICAL lab for boldenone)
- Therapeutic phlebotomy or blood donation if hematocrit exceeds 52-54%
- Total and free testosterone: baseline and mid-cycle to ensure testosterone base is adequate
- Estradiol (sensitive assay): monitor for low-estrogen symptoms, especially if EQ dose exceeds testosterone dose
- Comprehensive metabolic panel and lipid panel: baseline and every 8-12 weeks
- Blood pressure: regular monitoring throughout use, ideally weekly
- Liver function tests: baseline and periodic monitoring
- Kidney function (BUN, creatinine): baseline and periodic monitoring given renal clearance of metabolites
- Mental health assessment: monitor for anxiety, restlessness, and mood changes
References
Primary literature and clinical-trial data informing this entry.